The development of biologically active medication to treat

The development of biologically active medication to treat TBC patients Malkov S. А. , Shironosov O. V. , Shironosova G. I.

PROBLEM TOPICALITY WHO declared TBC the global danger in 1993. Every year TBC causes the following: l 1 billon people infection; l 8 -10 billion people illness; l 3 -4 billion people death.

Modern TBC patient treatment Is expensive (the average cost of one bed day 1600 rubles); l Causes poisonous effect; l Requires long-term (4 -6 months) administration; l Is aggravated by multidrug resistance. l

Galleria Mellonella – The Greater Wax Moth l l l I. I. Mechnikov (1889); S. А. Mukhin (1955); N. А. Spiridonov (1989). Extract's properties: 1. Immune protective; 2. Antimicrobial; 3. Antioxidant.

HOW TO GET A BIOACTIVE PRODUCT FROM THE GREATER WAX MOTH LARVAE (21)4938002/14 (22) 2603. 91 (46)2706. 95 Bulletin № 18 (71) Institute of Theoretical and Experimental Biophysics, USSR Academy of Sciences (72) Spiridonov NA; Rachkov AK; Mukhin SA; Kondrashova MN. (73) Spiridonov Nikolay Aleksandrovich (55) USSR certificate of authorship N 1284229, А 61 К 35/04. 1989.

The way of noncontact activation Solutions with negative redox potential are deoxidants; have powerful antioxidant features; improve permeability of biological membranes; improve the protective features of organism.

THE PROJET’S AIM is the development of bioactive medication (with long-lasting redox potential) on the basis of water solutions of The Greater Wax Moth larvae to treat TBC patients.

DYNAMICS OF REDOX POTENTIAL CHANGE Date Control (redox potential , m. V) Experiment (redox potential , m. V) 09. 07. 11 12. 08. 11 18. 08. 11 24. 08. 11 06. 09. 11 80 84 82 79 83 -193 -248 -301 -445 -476

Clinical research Republican tuberculosis dispensary: l l l 15 patients; Infiltrative TB. Average - 40 years; Gender - male; Treatment duration – 3, 5 months.

Research results ltwofold reduction of abacillary duration; lreduction of intoxication; limprovement of blood value (reduction of the number of lymphocytes, improvement of differential blood cell count, ESR reduction, etc. ).

Commercialization perspectives Bed day shortening by 1, 5 -2 times. l Treatment course depreciation. l Increase of medication’s biological activity. l

Demand assessment after launching: 1 st year (USD) 3 rd year (USD) Russia 50 000 200 000 CIS countries 70 000 300 000 ЕС countries, USA 100 000 350 000

GRNT - GLOBAL RESONANCE NONLINEAR TECHNOLOGIES Thank You and Be Healthy! http: //grnt. biz